MedTrace Logo

Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea

NCT03665428 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2020-05-21

No results posted yet for this study

Summary

South Korea has the highest incidence of gastric cancer worldwide and Helicobacter pylori infection is still prevalent. Clarithromycin-containing triple therapy is still the primary therapy approved by the Korean government. However, studies of antibiotic resistance has shown that regional resistance pattern to antibiotics such as clarithromycin, metronidazole, or quinolone. Recent study in Korea has shown that modified-quadruple therapy has comparable eradication rate to concomitant therapy. However, there has been no comparable study of modified-quadruple therapy with bismuth-containing quadruple therapy. The aim of this study is to compare the eradication rate of modified-quadruple therapy and bismuth-containing quadruple therapy with presenting phenotypic and genotypic antibiotic resistance profile.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

PAMB treatment (modified quadruple therapy)

Randomly assign either as PAMB or PBMT group treatment

DRUG

PBMT treatment (bismuth-containing quadruple therapy)

Randomly assign either as PAMB or PBMT group treatment

Sponsors & Collaborators

  • Hallym University Medical Center

    collaborator OTHER

  • Chuncheon Sacred Heart Hospital

    lead OTHER

Principal Investigators

  • Chang Seok Bang, MD, PhD · Hallym University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2019-08-06
Completion
2019-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03665428 on ClinicalTrials.gov